<DOC>
	<DOC>NCT01885585</DOC>
	<brief_summary>The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice</brief_summary>
	<brief_title>Eliquis Regulatory Post Marketing Surveillance (rPMS)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Signed data release Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty Being treated for an indication not approved for the use of Eliquis® in Korea Is contraindicated for the use of Eliquis® as described in the Korean label</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>